NTRK1 and renal cell carcinoma: Several multi-kinase inhibitors are currently in clinical use, indicating growing attention for multi-kinase inhibitors [12]; for example, multi-targeted receptor tyrosine kinase inhibitors, such as sorafenib—approved for the treatment of renal cell carcinoma (RCC) and hepatocellular carcinoma, and sunitinib—approved for the treatment of RCC and imatinib-resistant gastrointestinal stromal tumor have been developed [3,13,14].